Cencora, Inc.
USUSDCencora, Inc. (LSE:0HF3) — Other Pharmaceuticals. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 2. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par Uzņēmumu
- Tīmekļvietne
- cencora.com
- Nozare
- Health Care · Other Pharmaceuticals
- Galvenā Mītne
- Chesterbrook, United States
- Izpilddirektors
- Steven H. Collis
- Darbinieki
- 44 000
- Dibināts
- 2001
- Apgrozībā Esošās Akcijas
- 190.83 milj. uz 2026-07-31
- Brīvā Apgrozība
- 180.25 milj.
- Tirgus Kapitalizācija
- 58.98 mljrd. USD
- Iekšējās Personas
- 4.3%
- Institucionālie Investori
- 99.63%
- Nozare (SIC)
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- ISIN
- US03073E1055
- LEI
- AI8GXW8LG5WK7E9UD086
- Izmaksas Koeficients
- 17.8%
- FCF
- 4.06 mljrd. USD12%
- Parāds
- 11.7 mljrd. USD2.2 g. FCF
- Dividenžu Stāžs
- 25 g.
- Peļņa, FCF un izmaksātās dividendes — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Dividendes
Cencora, Inc. (COR) izmaksā dividendes reizi ceturksnī. Gadā (12 mēneši līdz jaunākajam paziņotajam maksājumam): 2.4 USD par akciju (maksājumi: 4). Tas ir aptuveni 0.74% no pašreizējās akciju cenas. Pamatojoties uz maksājumu vēsturi, nākamais ex-dividendes datums tiek gaidīts ap 13.11.2026. Nepārtrauktu dividenžu gadi: 25.
| Ex-Datums | Izmaksa | Summa | % | Veids | Tikeris |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-08-31 | 0.6000 USD | 0.2/0.7 % | ceturkšņa | US:COR |
| 2026-05-15 | 2026-06-01 | 0.6000 USD | 0.2/0.7 % | ceturkšņa | US:COR |
| 2026-02-13 | 2026-03-02 | 0.6000 USD | 0.2/0.7 % | ceturkšņa | US:COR |
| 2025-11-14 | 2025-12-01 | 0.6000 USD | 0.2/0.7 % | ceturkšņa | US:COR |
| 2025-08-15 | 2025-09-03 | 0.5500 USD | 0.2/0.7 % | ceturkšņa | US:COR |
| 2025-05-16 | 2025-06-02 | 0.5500 USD | 0.2/0.7 % | ceturkšņa | US:COR |
| 2025-02-14 | 2025-03-03 | 0.5500 USD | 0.2/≈0.7 % | ceturkšņa | US:COR |
| 2024-11-15 | 2024-11-29 | 0.5500 USD | 0.2/≈0.7 % | ceturkšņa | US:COR |
| 2024-08-09 | 2024-08-26 | 0.5100 USD | 0.2/≈0.6 % | ceturkšņa | US:COR |
Lielākie Akcionāri
| Turētājs | Daļa | Akcijas | Pārskata Datums |
|---|---|---|---|
| BlackRock | 9.54% | 18.21 milj. | 2026-06-30 |
| Vanguard Capital Managem… | 6.49% | 12.38 milj. | 2026-06-30 |
| Vanguard Portfolio Manag… | 5.04% | 9.61 milj. | 2026-06-30 |
| State Street Corporation | 4.86% | 9.27 milj. | 2026-06-30 |
| T. Rowe Price Investment… | 3.88% | 7.41 milj. | 2026-06-30 |
| Price (T.Rowe) Associate… | 3.74% | 7.13 milj. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.11% | 5.94 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.07% | 5.87 milj. | 2026-06-30 |
| Geode Capital Management… | 2.86% | 5.45 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.64% | 5.04 milj. | 2026-06-30 |
| Boston Partners | 2.55% | 4.87 milj. | 2026-06-30 |
| Wellington Management Gr… | 2.39% | 4.56 milj. | 2026-06-30 |
| T. ROWE PRICE CAPITAL AP… | 2.33% | 4.44 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.1% | 4.01 milj. | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 1.59% | 3.03 milj. | 2026-07-31 |
| iShares Trust-iShares Co… | 1.36% | 2.59 milj. | 2026-08-31 |
| Fidelity Concord Street… | 1.32% | 2.52 milj. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.25% | 2.38 milj. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.92% | 1.76 milj. | 2026-06-30 |
| -Price (T.Rowe) U.S. Val… | 0.85% | 1.62 milj. | 2026-06-30 |
| COLLIS STEVEN HOWARD (Of… | ≈0.16% | 305 913 | 2025-09-16 |
| CLEARY JAMES F. JR. (Chi… | ≈0.08% | 160 357 | 2026-03-11 |
| MAUCH ROBERT P. (Chief E… | ≈0.03% | 65 393 | 2026-02-20 |
| DURCAN DERMOT MARK (Dire… | ≈0.02% | 31 767 | 2026-06-18 |
| BATTAGLIA SILVANA (Offic… | ≈0.01% | 23 624 | 2026-06-30 |
| CAMPBELL ELIZABETH S (Of… | ≈0.01% | 19 455 | 2026-08-24 |
| GREENBERG LON R (Directo… | ≈0.01% | 17 128 | 2026-09-16 |
| KRIKORIAN LAZARUS (Offic… | ≈0.01% | 16 169 | 2026-09-01 |
| NALLY DENNIS M (Director… | ≈0.01% | 13 188 | 2026-07-31 |
| The Vanguard Group | — | — | — |
| Walgreens Boots Alliance… | — | — | 2025-02-06 |
